New pill may prevent chemotherapy delays in breast cancer patients
NCT ID NCT05394285
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called hetrombopag in 60 advanced breast cancer patients whose platelets dropped too low from chemotherapy. The goal was to see if the drug could safely raise platelet counts and prevent treatment delays or dose reductions. Patients took the pill daily when platelets were low, and doctors monitored their response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hetrombopag olamine tablets
What this could lead to
If it works, this could help advanced breast cancer patients avoid treatment delays or dose reductions due to low platelets, making chemotherapy safer and more effective.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to all patients. The drug may cause side effects or not work as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Henan Cancer Hospital
Zhengzhou, China